October 13th 2024
Data from the ARANOTE trial may support darolutamide plus androgen deprivation therapy as a standard of care in metastatic HSPC.
September 30th 2024
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
18th Annual New York GU Cancers Congress™
March 28-29, 2025
Register Now!
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Approval of Zoladex Is Recommended for Advanced Breast Ca
April 1st 1995ROCKVILLE, Md--In a nearly unanimous vote, the FDA's Oncologic Drugs Advisory Committee (ODAC) recommended that the agency approve a new indication for goserelin acetate implant (Zoladex), currently marketed as a prostate cancer therapy.
Selecting a Support Group for Patients With Prostate Carcinoma
March 1st 1995PHILADELPHIA--The burgeoning support group movement has much to offer patients with prostate cancer. Professionals who wish to refer patients to a support group, or to start their own group, should be aware of the several types of groups that
Emcyt/Taxol Studied in Refractory Prostate Ca
March 1st 1995PHILADELPHIA--Ongoing trials of a protocol that provides prolonged exposure to estramustine phosphate (Emcyt) and paclitaxel (Taxol) have produced promising results in men with hormone-refractory prostate cancer, Gary Hudes, MD, told Oncology News International.
PSA Shown to Predict Progression of Prostate Cancer
March 1st 1995CHICAGO--Proponents of the prostate-specific antigen (PSA) test have new ammunition to support the view that the controversial screening method accurately predicts the progression of prostate cancer and the long-term survival of patients,
Finasteride Studied as Prostate Ca Preventive
February 1st 1995NEW YORK--Finasteride (Pros-car), currently FDA approved for use in patients with symptomatic benign prostatic hyperplasia (BPH), is also being investigated as a prostate cancer treatment and is showing promise as an agent to prevent prostate cancer by reducing levels of dihydrotestosterone (DHT), Glenn J. Gormley, MD, PhD, said at the first International Conference on Cancer Prevention.
ACS Panel on Prostate Cancer: Painful Skeletal Mets Require Special Management
February 1st 1995PHILADELPHIA--Pain from skeletal metastasis has a major impact on quality of life in patients with prostate cancer, Mary Layman-Goldstein, RN, OCN, said at the American Cancer Society's National Conference on Prostate Cancer. Ms. Layman-Goldstein, a clinical nurse specialist at Memorial Sloan-Kettering Cancer Center, served on a panel discussion on how to manage complications of prostate cancer.
Improved Ultrasound Enhanses Diagnosis
February 1st 1995NEW YORK--Transrectal ultrasound is a valuable tool in the diagnosis of prostate cancer, but much can be done to optimize the procedure. W. Holt Sanders, MD, assistant professor of urology, Emory University School of Medicine, says that the basic principle is to "make sure the area of interest is within the focal range."
DNA Ploidy May Predict Course of Prostate Cancer
January 1st 1995CHICAGO--DNA ploidy in needle biopsy specimens is proving to be a highly accurate method of predicting local and distant spread of prostate cancer, as well as the probability of recurrence, Matthew Rifkin, MD, reported at the annual meeting of the Radiological Society of North America.
PSA Interpretation and Testing Can Be Made More Effective
January 1st 1995NEW YORK--Although it has revolutionized the early detection of prostate cancer, PSA testing can, and must, be improved to become the powerful tool needed in the fight against this disease, H. Ballentine Carter, MD, said at a conference on prostate cancer at Lenox Hill Hospital.
Laparoscopy May Have Limited Role In Prostate Cancer
January 1st 1995NEW YORK--Initial enthusiasm accompanying the introduction of laparoscopy in the diagnosis and treatment of prostate cancer has given way to a more realistic assessment of its value, R. Ernest Sosa, MD, said at a conference on prostate cancer at Lenox Hill Hospital. It continues to have value, but its role is limited and is unlikely to broaden.
Metastatic Prostate Cancer: Quality of Life and Cost Considerations
November 1st 1994The pharmacoeconomics of patient managementis important in the case of the critically ill. Pain palliationand improvements to quality of life are treatment goals for patientswith metastatic prostate cancer and can actually